Pegloticase and Methotrexate Co-Therapy for Lower Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with chronic refractory gout, who are allergic to conventional xanthine oxidase inhibitors or have failed to normalize serum uric acid levels, experience severe symptoms and immunogenicity issues with pegloticase therapy, leading to infusion reactions and loss of therapeutic response.
Innovation Solution
Co-administration of pegloticase with methotrexate (MTX) as an immunosuppressive agent to reduce immunogenicity and enhance therapeutic response, involving a 15 mg weekly MTX dose before and concurrent with pegloticase administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pegloticase is administered to reduce serum uric acid levels, then urate-lowering efficacy is improved, but immunogenicity increases leading to infusion reactions and loss of therapeutic response
Solution Approach 1:
Methotrexate is introduced as an intermediary substance that mediates between pegloticase and the patient's immune system. The immunosuppressive agent reduces antibody formation against pegloticase, thereby maintaining therapeutic efficacy while minimizing immunogenicity. This intermediary approach allows the primary drug to function effectively without triggering harmful immune responses.
Solution Approach 2:
The dosing regimen employs parameter changes by administering methotrexate at specific doses (e.g., 15-25 mg weekly) and timing it relative to pegloticase administration. By adjusting the immunosuppressive agent's dose and timing parameters, the treatment optimizes the balance between maintaining pegloticase efficacy and suppressing antibody formation, thereby resolving the contradiction between therapeutic benefit and immunogenicity.
2Reliability
If conventional xanthine oxidase inhibitors are used to treat gout, then serum uric acid levels are normalized, but allergic reactions occur in some patients
Solution Approach 1:
The invention extracts the problematic allergic reaction component by switching from xanthine oxidase inhibitors to pegloticase (uricase) therapy. By removing the offending substance class and replacing it with a different mechanism of action, the treatment achieves uric acid normalization through an alternative pathway that bypasses the allergenic trigger while maintaining therapeutic efficacy.
3Ease of operation
If pegloticase dosing frequency is reduced to every 4 weeks, then treatment simplicity is improved, but urate-lowering response is lost in many patients
Solution Approach 1:
Methotrexate is administered in advance (pre-dosing) before pegloticase treatment to suppress the immune system proactively. This preliminary immunosuppressive action prevents antibody formation that would otherwise occur with less frequent pegloticase dosing, thereby enabling extended dosing intervals while maintaining therapeutic response. The pre-action approach allows the system to tolerate lower drug frequencies without losing efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces infusion reactions, maintains serum uric acid normalization, and prolongs the urate-lowering effect by minimizing antibody formation and enhancing pegloticase efficacy in treating chronic gout.
Implementation Method 1
Pegloticase or PEGylated uricase (KRYSTEXXA®; 'KXX') is a monomethoxypoly(ethylene glycol) (PEG) modified recombinant mammalian uricase (urate oxidase) which reduces levels of UA in the serum (or plasma) by catalyzing its conversion to allantoin
Implementation Method 2
Co-administration of pegloticase with methotrexate (MTX) as an immunosuppressive agent to reduce immunogenicity and enhance therapeutic response
Data Source
AI summary
The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.